keyword
https://read.qxmd.com/read/38530098/trends-in-botulinum-toxin-related-industry-payments-to-physicians
#1
JOURNAL ARTICLE
Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan
Objectives: To evaluate trends in botulinum toxin (BTX) industry payments to physicians. Methods: Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. Results: Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8...
March 26, 2024: Facial plastic surgery & aesthetic medicine
https://read.qxmd.com/read/38427833/evaluating-the-effectiveness-of-lacrimal-gland-botulinum-toxin-using-the-tears-score
#2
JOURNAL ARTICLE
Samantha Vicki Hunt, Christopher Brian Schulz, Raman Malhotra
PURPOSE: Botulinum toxin (BoNTA) lacrimal gland injections are one treatment option for managing epiphora. Outcomes for epiphora in existing studies are subjective and lack grading. This study utilized validated grading instruments to evaluate the efficacy of BoNTA lacrimal gland injections. METHODS: Prospective study evaluating the TEARS score and quality of life in patients receiving incobotulinum toxin (Xeomin) lacrimal gland injections for epiphora. Epiphora was graded using the TEARS score...
March 2024: Ophthalmic Plastic and Reconstructive Surgery
https://read.qxmd.com/read/38307637/applications-for-neurotoxins-in-the-face-and-neck
#3
REVIEW
Elda Fisher
No abstract text is available yet for this article.
March 2024: Atlas of the Oral and Maxillofacial Surgery Clinics of North America
https://read.qxmd.com/read/37437657/effect-of-botulinum-toxin-type-a-in-functionality-synkinesis-and-quality-of-life-in-peripheral-facial-palsy-sequelae
#4
JOURNAL ARTICLE
U Díaz-Aristizabal, M Valdés-Vilches, T R Fernández-Ferreras, E Calero-Muñoz, E Bienzobas-Allué, L Aguilera-Ballester, J Carnicer-Cáceres
OBJECTIVES: This study aimed to assess the effects of botulinum toxin A (BTX-A) infiltration on face muscle function, synkinesis, and quality of life in patients with sequelae of peripheral facial palsy (PFP). MATERIAL AND METHODS: We present the results of a prospective study including a sample of 20 patients with sequelae of PFP (15 women, 5 men) who underwent BTX-A (Botox© or Xeomin©) infiltration. All patients had previously received personalised treatment with neuromuscular retraining...
July 10, 2023: Neurología
https://read.qxmd.com/read/37368677/outcomes-of-incobotulinumtoxina-injection-on-myalgia-and-arthralgia-in-patients-undergoing-temporomandibular-joint-arthroscopy-a-randomized-controlled-trial
#5
RANDOMIZED CONTROLLED TRIAL
David Faustino Ângelo, David Sanz, Francesco Maffia, Henrique José Cardoso
BACKGROUND: Several studies have considered Botulinum Neurotoxin Type A injections effective in treating temporomandibular joint disorder (TMD) symptoms. A double-blind, randomized, controlled clinical trial investigated the benefit of complementary incobotulinumtoxinA (inco-BoNT/A) injections in the masticatory muscles of patients submitted to bilateral temporomandibular joint (TMJ) arthroscopy. METHODS: Fifteen patients with TMD and an indication for bilateral TMJ arthroscopy were randomized into inco-BoNT/A (Xeomin, 100 U) or placebo groups (saline solution)...
June 3, 2023: Toxins
https://read.qxmd.com/read/37223298/trigeminal-neuralgia-incobotulinumtoxina-xeomin-can-it-decrease-the-pharmacological-intervention-a-case-series
#6
Meghdad Hosseini, Farhad Asarzadegan, Erfan Shafiee, Shayan Alijanpour
BACKGROUND: Trigeminal neuralgia is one of the most disabling facial pain syndromes. In recent years' new therapeutic strategy, incobotulinumtoxin A has emerged. The aim of the current study was to determine the time and duration of pain in 3 cases with pharmacological treatment and incobotulinumtoxin A. CASE PRESENTATION: In three patients with different onsets, trigeminal neuralgia was diagnosed. Pain severity was assessed by the visual analogue scale. Patient demographics and clinical data were filled in a checklist...
2023: Caspian Journal of Internal Medicine
https://read.qxmd.com/read/37183235/effects-of-lidocaine-incorporation-without-epinephrine-on-pain-and-2-week-complications-of-botulinum-toxin-a-double-blind-randomized-placebo-controlled-clinical-trial
#7
JOURNAL ARTICLE
Farzin Sarkarat, Diba Bagheri, Roozbeh Kahali, Ali Fateh, Vahid Rakhshan
No study has assessed the effects of the incorporation of isolated lidocaine into botulinum toxin for reducing its pain or complications. Studies on the dilution of botulinum toxin with other materials are as well extremely few, small, and limited methodologically. Therefore, we aimed to evaluate, for the first time, the effects of the incorporation of lidocaine alone into botulinum toxin type A on post-injection pain and complications. In this 2-week prospective, multicenter, double-blind randomized placebo-controlled clinical trial, 729 participants (667 females) were enrolled...
May 14, 2023: Scientific Reports
https://read.qxmd.com/read/37104185/xeomin-%C3%A2-a-commercial-formulation-of-botulinum-neurotoxin-type-a-promotes-regeneration-in-a-preclinical-model-of-spinal-cord-injury
#8
JOURNAL ARTICLE
Valentina Mastrorilli, Federica De Angelis, Valentina Vacca, Flaminia Pavone, Siro Luvisetto, Sara Marinelli
Xeomin® is a commercial formulation of botulinum neurotoxin type A (BoNT/A) clinically authorized for treating neurological disorders, such as blepharospasm, cervical dystonia, limb spasticity, and sialorrhea. We have previously demonstrated that spinal injection of laboratory purified 150 kDa BoNT/A in paraplegic mice, after undergoing traumatic spinal cord injury (SCI), was able to reduce excitotoxic phenomena, glial scar, inflammation, and the development of neuropathic pain and facilitate regeneration and motor recovery...
March 28, 2023: Toxins
https://read.qxmd.com/read/36988469/combining-topical-dermal-infused-exosomes-with-injected-calcium-hydroxylapatite-for-enhanced-tissue-biostimulation
#9
JOURNAL ARTICLE
Greg Chernoff
BACKGROUND: Exosome research continues to flourish. Subsequent knowledge surrounding indications, dose-response, safety, efficacy, and the ability to combine exosome treatment as a "skin primer"-for biostimulation modalities such as calcium hydroxylapatite (CaHA), platelet-rich plasma (PRP), and platelet-rich fibrin matrix (PRFM) is growing rapidly. The objective of this study was to develop safe, reproducible methods of improving topical exosome absorption to enhance the quality of skin either by themselves, or in combination with injectable CaHA...
March 2023: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/36987400/incobotulinumtoxina-for-the-treatment-of-glabella-and-forehead-dynamic-lines-a-real-life-longitudinal-case-series
#10
Ana Lucia Gonzaga da Cunha, Rossana Vasconcelos, David Di Sessa, Gabriel Sampaio, Pitila Ramalhoto, Bruno F Zampieri, Bárbara S Deus, Suyan Vasconcelos, Talitha Bellote, Juiano Carvalho, Giseli Petrone, Vinicius Figueredo, Gustavo Limongi Moreira
BACKGROUND: There is substantial interpersonal variation in the patterns of muscular contraction that substantiates the use of personalized points of application and dosages in clinical practice to achieve optimal results. Nevertheless, there has been no real-life therapeutic series with botulinum toxin for aesthetic treatment of the face in which the subjects were systematically followed to assess its long-term benefit. PURPOSE: To assess the performance and length of the treatment of glabellar and forehead lines with IncobotulinumtoxinA in a real-life setting...
2023: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/36810787/duration-of-bite-force-reduction-following-a-single-injection-of-botulinum-toxin-in-the-masseter-muscle-bilaterally-a-one-year-non-randomized-trial
#11
JOURNAL ARTICLE
Martin Ågren, Yanisorn Nanchaipruek, Phumithep Phumariyapong, Chalermkwan Apinuntham, Sarawalai Rakchart, Mattias Pettersson, Rungsima Wanitphakdeedecha
BACKGROUND: Previous studies concerning the effect of botulinum toxin in masseter muscle have mainly reported effects observed through inspection of facial features or differences in pain levels. One systematic review of studies utilizing objective measurements reported that long-term muscular effect of botulinum neurotoxin injections into masseter muscle was inconclusive. OBJECTIVE: To evaluate the duration of reduced maximal voluntary bite force (MVBF) after botulinum toxin intervention...
May 2023: Journal of Oral Rehabilitation
https://read.qxmd.com/read/36587368/nonsurgical-treatment-for-upper-eyelid-retraction-in-patients-with-inactive-graves-orbitopathy
#12
JOURNAL ARTICLE
Sandra Vokurka Topljak, Martina Galiot Delić, Krešimir Mandić, Sanja Perić, Maja Baretić, Jelena Juri Mandić
PURPOSE: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin® ) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. METHODS: This is a comparative, prospective study, conducted at the Department of Ophthalmology, Medical School, University Hospital Centre Zagreb, EUGOGO site (EUropean Group On Graves' Orbitopathy) in Croatia from January 2020 till January of 2021 in accordance with national health headquarter recommendations...
January 1, 2023: International Ophthalmology
https://read.qxmd.com/read/36522255/botulinum-toxin-in-the-management-of-myalgia-in-temporomandibular-disorders-are-all-injections-equal
#13
JOURNAL ARTICLE
Haleemah Anwar, Alan Attard, Jason Green, Ross O C Elledge
Botulinum toxin (BTX) is becoming widely used as an adjunct to conservative management of myalgia-predominant temporomandibular disorders (TMDs) with reports of improved quality of life. There is, however, no consensus on the optimal dosage. Based on previous studies, dose regimens vary between clinicians, and we know of no standard dose protocol for the administration of BTX for the purpose of TMD management. A survey was sent to members of the British Association of Oral and Maxillofacial Surgeons (BAOMS) Temporomandibular Joint Sub-Specialty Interest Group (TMJ SSIG) and an international mailing list of high-volume TMJ surgeons (the TMJ Internetwork) to ascertain variations in dose regimens between different clinicians...
January 2023: British Journal of Oral & Maxillofacial Surgery
https://read.qxmd.com/read/36440782/-safety-and-efficacy-of-the-relatox-in-the-treatment-of-patients-with-cervical-dystonia-results-of-a-multicenter-simple-blind-comparative-randomized-study
#14
RANDOMIZED CONTROLLED TRIAL
S E Khatkova, O R Orlova, D V Pokhabov, V P Diagileva, S A Novikov, O A Pogoreltseva, V S Shevchenko, E A Nikolaev
OBJECTIVE: The analysis of evaluation of the efficacy and safety of Relatox in patients with cervical dystonia (CD). MATERIAL AND METHODS: Russian multicenter simple comparative randomized clinical trial. The study involved 180 patients of both sexes aged 18-65 years from 3 research centers of the Russian Federation. All patients had previously established diagnosis of CD and were randomized to one of two groups at 1 visit after the inclusion procedure and signing of informed consent...
2022: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://read.qxmd.com/read/36055061/incobotulinimtoxina-xeomin-for-the-treatment-of-adductor-laryngeal-dystonia-a-prospective-open-label-clinical-trial
#15
JOURNAL ARTICLE
Nikita Kohli, Michael Lerner, Jamie Rashty, Diana Kirke, Thomas Stewart, Andrew Blitzer
OBJECTIVES: Demonstrate an understanding of incobotulinumtoxinA efficacy in the treatment of adductor spasmodic dysphonia (SD). Understand that incobotulinumtoxinA can successfully be used as an alternative to onabotulinumtoxinA and for secondary non-responders. METHODS: We conducted a prospective open-label trial from 2016 until 2019 regarding the use of incobotulinimtoxinA for the treatment of adductor spasmodic dysphonia. Exclusion criteria included pregnant/nursing women, botulinum toxin for other indications, known allergy, neuromuscular or systemic diseases, use of aminoglycoside antibiotics, substance abuse, litigation regarding prior therapy, or other confounding conditions...
2022: American Journal of Otolaryngology
https://read.qxmd.com/read/36006219/real-world-longitudinal-experience-of-botulinum-toxin-therapy-for-parkinson-and-essential-tremor
#16
JOURNAL ARTICLE
Olivia Samotus, Yekta Mahdi, Mandar Jog
BACKGROUND: Botulinum toxin type A (BoNT-A) therapy for upper-limb tremor has emerged as a promising option. However, it is unclear in real-world practices whether a technology-guided approach can compare with expert clinical assessments (including surface anatomy and palpation) for improving outcomes. This retrospective study aims to review our clinical outcomes of treating essential tremor (ET) and Parkinson's disease (PD) tremor using either clinical- or kinematic-based injection pattern determination methods...
August 17, 2022: Toxins
https://read.qxmd.com/read/35737026/comparative-pharmacodynamics-of-three-different-botulinum-toxin-type-a-preparations-following-repeated-intramuscular-administration-in-mice
#17
JOURNAL ARTICLE
Jaeyoon Byun, Seongsung Kwak, Jin-Hee Kwon, Minhee Shin, Dong-Kyu Lee, Chang-Hoon Rhee, Won-Ho Kang, Jae-Wook Oh, Deu John M Cruz
Botulinum neurotoxin type A (BoNT/A) causes muscle paralysis by blocking cholinergic signaling at neuromuscular junctions and is widely used to temporarily correct spasticity-related disorders and deformities. The paralytic effects of BoNT/A are time-limited and require repeated injections at regular intervals to achieve long-term therapeutic benefits. Differences in the level and duration of effectivity among various BoNT/A products can be attributed to their unique manufacturing processes, formulation, and noninterchangeable potency units...
May 25, 2022: Toxins
https://read.qxmd.com/read/35675468/-cosmeticstwitter-predicting-public-interest-in-nonsurgical-cosmetic-procedures-using-twitter-data
#18
JOURNAL ARTICLE
Samuel A Cohen, Jonathan D Tijerina, Shreya A Shah, Linus Amarikwa, Andrea L Kossler
BACKGROUND: The use of social media in plastic surgery is expanding. The Twitter Academic Research Product Tract (TARPT) database provides plastic surgeons the opportunity to monitor public interest in plastic surgery procedures. Previously, TARPT has been shown to be effective in tracking public interest in surgical cosmetic facial and body procedures. OBJECTIVES: To determine the ability of the TARPT tool to track and predict public interest in nonsurgical cosmetic procedures and to examine temporal public interest trends in nonsurgical cosmetic procedures...
June 8, 2022: Aesthetic Surgery Journal
https://read.qxmd.com/read/35453158/-treatment-of-sialorrhea-with-botulinum-neurotoxin-type-a-consensus-practice-recommendations-for-children-and-adults
#19
JOURNAL ARTICLE
Wolfgang H Jost, Tobias Bäumer, Andrea Bevot, Ulrich Birkmann, Carsten Buhmann, Maria Grosheva, Orlando Guntinas-Lichius, Ute Mlynczak, Sebastian Paus, Christina Pflug, Sebastian Schröder, Armin Steffen, Bernd Wilken, Steffen Berweck
Sialorrhea, uncontrolled, excessive drooling, accompanies different, mostly neurological disorders from childhood to adulthood. With incobotulinumtoxinA (Xeomin, IncoBoNT/A, Merz Pharmaceuticals GmbH), an approved medication for the treatment of sialorrhea has been available since 2019. Patient selection, possible therapy goals, treatment and the management of specific treatment situations build the focus of this interdisciplinary expert consensus recommendations with the intent to facilitate access to treatment and to contribute to qualified botulinum toxin therapy...
May 2022: Fortschritte der Neurologie-Psychiatrie
https://read.qxmd.com/read/35448895/effectiveness-and-safety-of-intracavernosal-incobotulinumtoxina-xeomin-%C3%A2-100-u-as-an-add-on-therapy-to-standard-pharmacological-treatment-for-difficult-to-treat-erectile-dysfunction-a-case-series
#20
RANDOMIZED CONTROLLED TRIAL
Francois Giuliano, Pierre Denys, Charles Joussain
Registered pharmacological treatments are insufficiently effective for erectile dysfunction (ED) in around 30% of affected men. Intracavernosal injection (ICI) of ona- and abobotulinumtoxinA can reduce ED in insufficient responders. We aimed to assess the safety and effectiveness of incobotulinumtoxinA ICI as an add-on therapy to phosphodiesterase-type 5 inhibitors (PDE5-Is) or prostaglandinE1 ICIs (PGE1 ICIs) to treat ED that did not respond sufficiently to this treatment alone. We retrospectively analyzed data from 66 men with difficult to treat ED treated with single or repeated incobotulinumtoxinA 100U ICI as an add-on therapy...
April 16, 2022: Toxins
keyword
keyword
9456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.